Cargando…

Molecular benchmarks of a SARS-CoV-2 epidemic

A pressing concern in the SARS-CoV-2 epidemic and other viral outbreaks, is the extent to which the containment measures are halting the viral spread. A straightforward way to assess this is to tally the active cases and the recovered ones throughout the epidemic. Here, we show how epidemic control...

Descripción completa

Detalles Bibliográficos
Autores principales: Jonsson, Hakon, Magnusson, Olafur T., Melsted, Pall, Berglund, Jonas, Agustsdottir, Arna B., Eiríksdottir, Berglind, Fridriksdottir, Run, Garðarsdottir, Elisabet Eir, Georgsson, Gudmundur, Gretarsdottir, Olafia S., Guðmundsson, Kjartan R., Gunnarsdottir, Thora Rosa, Eggertsson, Hannes, Gylfason, Arnaldur, Holm, Hilma, Jensson, Brynjar O., Jonasdottir, Aslaug, Jonsson, Frosti, Josefsdottir, Kamilla S., Thordardottir, Marianna, Kristinsson, Karl G., Kristjánsson, Þórður, Magnusdottir, Droplaug N., Roux, Louise le, Saemundsdottir, Jona, Sigurdsson, Asgeir, Sigmundsdottir, Gudrun, Sveinbjornsson, Gardar, Rognvaldsson, Solvi, Eiriksson, Ogmundur, Magnusson, Magnus Karl, Sveinsdottir, Kristin Eva, Sveinsdottir, Maney, Thorarensen, Emil Aron, Thorbjornsson, Bjarni, Löve, Arthur, Norddahl, Gudmundur L., Jonsdottir, Ingileif, Sulem, Patrick, Masson, Gisli, Moller, Alma, Gudnason, Thorolfur, Kristjansson, Mar, Helgason, Agnar, Gudbjartsson, Daniel F., Thorsteinsdottir, Unnur, Stefansson, Kari
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8206085/
https://www.ncbi.nlm.nih.gov/pubmed/34131116
http://dx.doi.org/10.1038/s41467-021-23883-6
_version_ 1783708571923382272
author Jonsson, Hakon
Magnusson, Olafur T.
Melsted, Pall
Berglund, Jonas
Agustsdottir, Arna B.
Eiríksdottir, Berglind
Fridriksdottir, Run
Garðarsdottir, Elisabet Eir
Georgsson, Gudmundur
Gretarsdottir, Olafia S.
Guðmundsson, Kjartan R.
Gunnarsdottir, Thora Rosa
Eggertsson, Hannes
Gylfason, Arnaldur
Holm, Hilma
Jensson, Brynjar O.
Jonasdottir, Aslaug
Jonsson, Frosti
Josefsdottir, Kamilla S.
Thordardottir, Marianna
Kristinsson, Karl G.
Kristjánsson, Þórður
Magnusdottir, Droplaug N.
Roux, Louise le
Saemundsdottir, Jona
Sigurdsson, Asgeir
Sigmundsdottir, Gudrun
Sveinbjornsson, Gardar
Rognvaldsson, Solvi
Eiriksson, Ogmundur
Magnusson, Magnus Karl
Sveinsdottir, Kristin Eva
Sveinsdottir, Maney
Thorarensen, Emil Aron
Thorbjornsson, Bjarni
Löve, Arthur
Norddahl, Gudmundur L.
Jonsdottir, Ingileif
Sulem, Patrick
Masson, Gisli
Moller, Alma
Gudnason, Thorolfur
Kristjansson, Mar
Helgason, Agnar
Gudbjartsson, Daniel F.
Thorsteinsdottir, Unnur
Stefansson, Kari
author_facet Jonsson, Hakon
Magnusson, Olafur T.
Melsted, Pall
Berglund, Jonas
Agustsdottir, Arna B.
Eiríksdottir, Berglind
Fridriksdottir, Run
Garðarsdottir, Elisabet Eir
Georgsson, Gudmundur
Gretarsdottir, Olafia S.
Guðmundsson, Kjartan R.
Gunnarsdottir, Thora Rosa
Eggertsson, Hannes
Gylfason, Arnaldur
Holm, Hilma
Jensson, Brynjar O.
Jonasdottir, Aslaug
Jonsson, Frosti
Josefsdottir, Kamilla S.
Thordardottir, Marianna
Kristinsson, Karl G.
Kristjánsson, Þórður
Magnusdottir, Droplaug N.
Roux, Louise le
Saemundsdottir, Jona
Sigurdsson, Asgeir
Sigmundsdottir, Gudrun
Sveinbjornsson, Gardar
Rognvaldsson, Solvi
Eiriksson, Ogmundur
Magnusson, Magnus Karl
Sveinsdottir, Kristin Eva
Sveinsdottir, Maney
Thorarensen, Emil Aron
Thorbjornsson, Bjarni
Löve, Arthur
Norddahl, Gudmundur L.
Jonsdottir, Ingileif
Sulem, Patrick
Masson, Gisli
Moller, Alma
Gudnason, Thorolfur
Kristjansson, Mar
Helgason, Agnar
Gudbjartsson, Daniel F.
Thorsteinsdottir, Unnur
Stefansson, Kari
author_sort Jonsson, Hakon
collection PubMed
description A pressing concern in the SARS-CoV-2 epidemic and other viral outbreaks, is the extent to which the containment measures are halting the viral spread. A straightforward way to assess this is to tally the active cases and the recovered ones throughout the epidemic. Here, we show how epidemic control can be assessed with molecular information during a well characterized epidemic in Iceland. We demonstrate how the viral concentration decreased in those newly diagnosed as the epidemic transitioned from exponential growth phase to containment phase. The viral concentration in the cases identified in population screening decreased faster than in those symptomatic and considered at high risk and that were targeted by the healthcare system. The viral concentration persists in recovering individuals as we found that half of the cases are still positive after two weeks. We demonstrate that accumulation of mutations in SARS-CoV-2 genome can be exploited to track the rate of new viral generations throughout the different phases of the epidemic, where the accumulation of mutations decreases as the transmission rate decreases in the containment phase. Overall, the molecular signatures of SARS-CoV-2 infections contain valuable epidemiological information that can be used to assess the effectiveness of containment measures.
format Online
Article
Text
id pubmed-8206085
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-82060852021-07-01 Molecular benchmarks of a SARS-CoV-2 epidemic Jonsson, Hakon Magnusson, Olafur T. Melsted, Pall Berglund, Jonas Agustsdottir, Arna B. Eiríksdottir, Berglind Fridriksdottir, Run Garðarsdottir, Elisabet Eir Georgsson, Gudmundur Gretarsdottir, Olafia S. Guðmundsson, Kjartan R. Gunnarsdottir, Thora Rosa Eggertsson, Hannes Gylfason, Arnaldur Holm, Hilma Jensson, Brynjar O. Jonasdottir, Aslaug Jonsson, Frosti Josefsdottir, Kamilla S. Thordardottir, Marianna Kristinsson, Karl G. Kristjánsson, Þórður Magnusdottir, Droplaug N. Roux, Louise le Saemundsdottir, Jona Sigurdsson, Asgeir Sigmundsdottir, Gudrun Sveinbjornsson, Gardar Rognvaldsson, Solvi Eiriksson, Ogmundur Magnusson, Magnus Karl Sveinsdottir, Kristin Eva Sveinsdottir, Maney Thorarensen, Emil Aron Thorbjornsson, Bjarni Löve, Arthur Norddahl, Gudmundur L. Jonsdottir, Ingileif Sulem, Patrick Masson, Gisli Moller, Alma Gudnason, Thorolfur Kristjansson, Mar Helgason, Agnar Gudbjartsson, Daniel F. Thorsteinsdottir, Unnur Stefansson, Kari Nat Commun Article A pressing concern in the SARS-CoV-2 epidemic and other viral outbreaks, is the extent to which the containment measures are halting the viral spread. A straightforward way to assess this is to tally the active cases and the recovered ones throughout the epidemic. Here, we show how epidemic control can be assessed with molecular information during a well characterized epidemic in Iceland. We demonstrate how the viral concentration decreased in those newly diagnosed as the epidemic transitioned from exponential growth phase to containment phase. The viral concentration in the cases identified in population screening decreased faster than in those symptomatic and considered at high risk and that were targeted by the healthcare system. The viral concentration persists in recovering individuals as we found that half of the cases are still positive after two weeks. We demonstrate that accumulation of mutations in SARS-CoV-2 genome can be exploited to track the rate of new viral generations throughout the different phases of the epidemic, where the accumulation of mutations decreases as the transmission rate decreases in the containment phase. Overall, the molecular signatures of SARS-CoV-2 infections contain valuable epidemiological information that can be used to assess the effectiveness of containment measures. Nature Publishing Group UK 2021-06-15 /pmc/articles/PMC8206085/ /pubmed/34131116 http://dx.doi.org/10.1038/s41467-021-23883-6 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Jonsson, Hakon
Magnusson, Olafur T.
Melsted, Pall
Berglund, Jonas
Agustsdottir, Arna B.
Eiríksdottir, Berglind
Fridriksdottir, Run
Garðarsdottir, Elisabet Eir
Georgsson, Gudmundur
Gretarsdottir, Olafia S.
Guðmundsson, Kjartan R.
Gunnarsdottir, Thora Rosa
Eggertsson, Hannes
Gylfason, Arnaldur
Holm, Hilma
Jensson, Brynjar O.
Jonasdottir, Aslaug
Jonsson, Frosti
Josefsdottir, Kamilla S.
Thordardottir, Marianna
Kristinsson, Karl G.
Kristjánsson, Þórður
Magnusdottir, Droplaug N.
Roux, Louise le
Saemundsdottir, Jona
Sigurdsson, Asgeir
Sigmundsdottir, Gudrun
Sveinbjornsson, Gardar
Rognvaldsson, Solvi
Eiriksson, Ogmundur
Magnusson, Magnus Karl
Sveinsdottir, Kristin Eva
Sveinsdottir, Maney
Thorarensen, Emil Aron
Thorbjornsson, Bjarni
Löve, Arthur
Norddahl, Gudmundur L.
Jonsdottir, Ingileif
Sulem, Patrick
Masson, Gisli
Moller, Alma
Gudnason, Thorolfur
Kristjansson, Mar
Helgason, Agnar
Gudbjartsson, Daniel F.
Thorsteinsdottir, Unnur
Stefansson, Kari
Molecular benchmarks of a SARS-CoV-2 epidemic
title Molecular benchmarks of a SARS-CoV-2 epidemic
title_full Molecular benchmarks of a SARS-CoV-2 epidemic
title_fullStr Molecular benchmarks of a SARS-CoV-2 epidemic
title_full_unstemmed Molecular benchmarks of a SARS-CoV-2 epidemic
title_short Molecular benchmarks of a SARS-CoV-2 epidemic
title_sort molecular benchmarks of a sars-cov-2 epidemic
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8206085/
https://www.ncbi.nlm.nih.gov/pubmed/34131116
http://dx.doi.org/10.1038/s41467-021-23883-6
work_keys_str_mv AT jonssonhakon molecularbenchmarksofasarscov2epidemic
AT magnussonolafurt molecularbenchmarksofasarscov2epidemic
AT melstedpall molecularbenchmarksofasarscov2epidemic
AT berglundjonas molecularbenchmarksofasarscov2epidemic
AT agustsdottirarnab molecularbenchmarksofasarscov2epidemic
AT eiriksdottirberglind molecularbenchmarksofasarscov2epidemic
AT fridriksdottirrun molecularbenchmarksofasarscov2epidemic
AT garðarsdottirelisabeteir molecularbenchmarksofasarscov2epidemic
AT georgssongudmundur molecularbenchmarksofasarscov2epidemic
AT gretarsdottirolafias molecularbenchmarksofasarscov2epidemic
AT guðmundssonkjartanr molecularbenchmarksofasarscov2epidemic
AT gunnarsdottirthorarosa molecularbenchmarksofasarscov2epidemic
AT eggertssonhannes molecularbenchmarksofasarscov2epidemic
AT gylfasonarnaldur molecularbenchmarksofasarscov2epidemic
AT holmhilma molecularbenchmarksofasarscov2epidemic
AT jenssonbrynjaro molecularbenchmarksofasarscov2epidemic
AT jonasdottiraslaug molecularbenchmarksofasarscov2epidemic
AT jonssonfrosti molecularbenchmarksofasarscov2epidemic
AT josefsdottirkamillas molecularbenchmarksofasarscov2epidemic
AT thordardottirmarianna molecularbenchmarksofasarscov2epidemic
AT kristinssonkarlg molecularbenchmarksofasarscov2epidemic
AT kristjanssonþorður molecularbenchmarksofasarscov2epidemic
AT magnusdottirdroplaugn molecularbenchmarksofasarscov2epidemic
AT rouxlouisele molecularbenchmarksofasarscov2epidemic
AT saemundsdottirjona molecularbenchmarksofasarscov2epidemic
AT sigurdssonasgeir molecularbenchmarksofasarscov2epidemic
AT sigmundsdottirgudrun molecularbenchmarksofasarscov2epidemic
AT sveinbjornssongardar molecularbenchmarksofasarscov2epidemic
AT rognvaldssonsolvi molecularbenchmarksofasarscov2epidemic
AT eirikssonogmundur molecularbenchmarksofasarscov2epidemic
AT magnussonmagnuskarl molecularbenchmarksofasarscov2epidemic
AT sveinsdottirkristineva molecularbenchmarksofasarscov2epidemic
AT sveinsdottirmaney molecularbenchmarksofasarscov2epidemic
AT thorarensenemilaron molecularbenchmarksofasarscov2epidemic
AT thorbjornssonbjarni molecularbenchmarksofasarscov2epidemic
AT lovearthur molecularbenchmarksofasarscov2epidemic
AT norddahlgudmundurl molecularbenchmarksofasarscov2epidemic
AT jonsdottiringileif molecularbenchmarksofasarscov2epidemic
AT sulempatrick molecularbenchmarksofasarscov2epidemic
AT massongisli molecularbenchmarksofasarscov2epidemic
AT molleralma molecularbenchmarksofasarscov2epidemic
AT gudnasonthorolfur molecularbenchmarksofasarscov2epidemic
AT kristjanssonmar molecularbenchmarksofasarscov2epidemic
AT helgasonagnar molecularbenchmarksofasarscov2epidemic
AT gudbjartssondanielf molecularbenchmarksofasarscov2epidemic
AT thorsteinsdottirunnur molecularbenchmarksofasarscov2epidemic
AT stefanssonkari molecularbenchmarksofasarscov2epidemic